CD38 and Miyoshi myopathy: Furthermore, both AZA and DAC were only very recently shown to restore sensitivity to the monoclonal anti-CD38 Ab daratumumab in MM cell lines, by reverting epigenetic silencing of CD38 upon daratumumab treatment (214).